针对新兴感染疾病威胁的医护站诊断(市场分析与技术考察) 是由出版商Kalorama Information在2011年10月所出版的。
这份英文市场调查报告书包含150 Pages 价格从美金3500起跳。
本报告提供医护站诊断整体市场概要，以及感染疾病的POC市场主要企业简介， 国际计划概要，各不同疾病趋势与到2015年为止的预测等汇整数据，为您概述为以下内容。
第1卷 摘要整理
第2章 感染疾病相关分布式检测设备的商业化
- 概要
- 用户培训与支持服务
- 连接性支持分散检测
- 病患的负担
- 药物体制复杂化测试环境
- 未满足需求
- 财政，国际计划的经济学
- 结论
第3章 技术考察
- 概要
- 试剂问题
- 设备·非设备
- 血糖试纸的诊断
- 分子诊断的潜力
- 无线通讯
- 小型化
第4章 南美锥虫病
- 简介
- 各地区市场
- 国际计划
- 检验现况
- 参与企业
- 检验技术:现在和未来
第5章 基孔肯雅热
- 简介
- 各地区市场
- 国际计划
- 检验现况
- 参与企业
- 检验技术:现在和未来
第6章 登革热
- 简介
- 各地区市场
- 国际计划
- 检验现况
- 参与企业
- 检验技术:现在和未来
第7章 HIV
- 简介
- 各地区市场
- 国际计划
- 检验现况
- 参与企业
- 检验技术:现在和未来
第8章 人类乳突病毒(HPV)
- 简介
- 各地区市场
- 国际计划
- 检验现况
- 参与企业
- 检验技术:现在和未来
第9章 利什曼症
- 简介
- 各地区市场
- 国际计划
- 检验现况
- 参与企业
- 检验技术:现在和未来
第10章 钩端螺旋体病
- 简介
- 各地区市场
- 国际计划
- 检验现况
- 参与企业
- 检验技术:现在和未来
第11章 疟疾
- 简介
- 各地区市场
- 国际计划
- 检验现况
- 参与企业
- 检验技术:现在和未来
第12章 盘尾丝虫病
- 简介
- 各地区市场
- 国际计划
- 检验现况
- 参与企业
- 检验技术:现在和未来
第13章 STD
- 简介
- 各地区市场
- 国际计划
- 检验现况
- 参与企业
- 检验技术:现在和未来
第14章 结核
- 简介
- 各地区市场
- 国际计划
- 检验现况
- 参与企业
- 检验技术:现在和未来
Abstract
The World Health Organization has identified a group of diseases that are the
world' s most pressing health problems. This represents an opportunity for test
manufacturers, particularly in POC testing. Because of their ability to
deliver fast results at the point of care, rapid testing is a focus area of
healthcare providers and payors in infectious disease prevention. Kalorama
Information has been reporting on the rapid test area for several years and
has identified the segments with the fastest growth, and infectious disease
has surfaced as one of those segments.
This report, Point of Care Diagnostics for Emerging Infectious Disease Threats
(Market Analysis and Technical Considerations), examines this POC segment with
a focus on new threats for which there are markets in the developing world and
in developed countries.
A Unique Approach: Market and Technical Analysis
Tests can only be marketed if they can be manufactured and if they can
function in the healthcare environment. Thus, this report also discusses the
technical choices, possibilities and limitations to today' s POC tests
especially when they are used in the developing world. Reagent issues, testing
on strips, instrumented and non-instrumented tests are coved in this report.
These factors will impact what tests will reach the market and how they will
function.
An Opportunity For Test Makers
Infectious disease is a broad category, and in some disease areas, diagnostic
companies already own market share. Increasingly hospitals and clinics are
seeing new infectious disease threats and tests are being developed to assist
them. Within the infectious disease testing market, this report details the
opportunities that could be found when diseases of the developing world enter
the healthcare system of the developed. This report provides market
projections for point of care diagnostics in the developed and developing
world for the following infectious diseases:
- Chagas Disease, Rapid Test Market Forecast to 2015
- Chikungunya, Rapid Test Market Forecast to 2015
- Dengue Fever, Rapid Test Market Forecast to 2015
- HIV, Rapid Test Market Current Size and Forecast to 2015
- HPV, Rapid Test Market Current Size and Forecast to 2015
- Leishmaniasis, Rapid Test Market Forecast to 2015
- Onchocerciasis (River Blindness), Rapid Test Market Forecast to 2015
- STDs, Rapid Test Market Current Size and Forecast to 2015
- Tuberculosis, Rapid Test Market Forecast to 2015
In addition the report also provides:
- The Overall Point of Care Diagnostics Market Statistics
- Economics of Financial and International Programs
- Company Profiles of Leaders in the POC Infectious Disease Market
- Key Players in the Infectious Disease Rapid Test Market
- Developed and Developing World Opportunities
- Test Volumes in Developing Countries
- Review of Test Products Currently on the Market
- Climate, Water Use and Sample Prep Considerations
- EMR and Connectivity Issues
- Tests in Development
- The Role of Drug Resistance
- Disease Statistics
- POC and Infrastructure Needs
- Comparison of Test Modalities and Sample Collection Methods
Two Industry Experts Provide Unique Insights
Shara Rosen is Kalorama Information' s lead diagnostic industry analyst. She is
the author of seven best-selling editions of The Worldwide Market for In Vitro
Diagnostics, as well as scores of other titles on segments of the IVD Industry.
Brendan O' Farrell is the President of Diagnostic Consulting Network
, a provider of OEM services to developers and manufacturers of
rapid assays. Key services include contract rapid assay system development,
custom reagent development, industry education and training and consulting
services. Among the topics these experts discuss is the number of competitors
who have been successful with efforts in developing countries.
The following companies are discussed in this report:
- 3QBD
- Abbott Diagnostics Access Bio, Inc.
- Acon Laboratories, Inc./Innovacon
- Akers Biosciences, Inc.
- Akonni Biosystems Inc.
- Alere
- American Bionostica, Inc.
- AT First Diagnostic LLC
- Beckman Coulter Inc. Becton Dickinson
- Bhat Bio-tech India (p) Ltd.
- Biocan Diagnostics Inc.
- bioLytical Laboratories
- Biomagnetics Diagnostics Corp.
- Bio-Manguinhos/FioCruz
- bioMerieux
- BioVei Incorporated
- Burnet Institute
- California Institute of Technology (Caltech)
- CapitalBio Corporation
- Catalysis Foundation for Health
- Cellestis Ltd
- Cepheid
- Chembio Diagnostic Systems, Inc.
- Clearbridge BioLoc
- Clinoteck Diagnostics
- Core Diagnostics
- CTK Biotech Inc.
- Diagnostics for All (DFA)
- Diagnostics for the Real World (DRW)
- DIALAB
- DNA Medicine Institute (DMI)
- Eiken Chemical Co., Ltd.
- Enigma Diagnostics Limited
- Epistem Plc
- FK Biotecnologia
- Guardian Technologies International
- Hain Lifescience GmbH
- Hema Diagnostic Systems (HDS)
- i+MED Laboratories Company Limited
- InBios International, Inc.
- Ionian Technologies, Inc.
- IQuum Inc.
- Jal Innovation (S) Pte
- LabNow
- Lifeassay Diagnostics (Pty) Ltd
- Linnodee Ltd.
- LumiQuick Diagnostics, Inc.
- J. Mitra & Co. Pvt Ltd
- MP Biomedicals
- MedMira Inc.
- Micronics, Inc.
- Microskia
- Millennium Biotechnology, Inc. (MBI)
- Omega Diagnostics Group PLC
- Partec GmbH
- PointCare Technologies, Inc.
- QBC Diagnostics, Inc.
- QuantuMDx Group
- Premier Medical Corporation Limited
- Princeton BioMeditech Corporation
- Seventh Sense Biosystems, Inc.
- Signature Mapping Medical Sciences, Inc.
- Span Diagnostics Ltd.
- Standard Diagnostics, Inc.
- Tulip Group
- VEDA.LAB
- Veredus Laboratories Pte
- WAMA Diagnostica
- Zyomyx Inc.
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
- Scope and Methodology
- Emerging Market Trends, diseases and technologies
- World Demand for Decentralized Testing for Infectious Diseases
CHAPTER TWO: COMMERCIALIZATION OF DECENTRALIZED TEST DEVICES FOR INFECTIOUS DISEASES
- Overview
- User Training and Support Services
- Connectivity Supports Decentralized Testing
- The Disease Burden
- Drug Resistance Complicates the Test Landscape
- An Unmet Need
- Economics of Financial and International Programs
- Conclusion
CHAPTER THREE: TECHNICAL CONSIDERATIONS
- Overview
- Reagent Issues
- Instrumented or non-instrumented
- Diagnostics on Paper Test Strips
- The Promise of Decentralized Molecular Diagnostics
- Wireless Communication
- Miniaturization
CHAPTER FOUR: CHAGAS DISEASE
- Introduction: Key Comment
- Geographic Markets
- International Programs
- Status quo in testing
- Players
- Test technologies, now and future
CHAPTER FIVE: CHIKUNGUNYA
- Introduction: Key Comment
- Geographic Markets
- International Programs
- Status quo in testing
- Players
- Test technologies, now and future
CHAPTER SIX: DENGUE
- Introduction: Key Comment
- Geographic Markets
- International Programs
- Status quo in testing
- Players
- Test technologies, now and future
CHAPTER SEVEN: HIV
- Introduction: Key Comment
- Geographic Markets
- International Programs
- Status quo in testing
- Players
- Test technologies, now and future
CHAPTER EIGHT: HPV
- Introduction: Key Comment
- Geographic Markets
- International Programs
- Status quo in testing
- Players
- Test technologies, now and future
CHAPTER NINE: LEISHMANIASIS
- Introduction: Key Comment
- Geographic Markets
- International Programs
- Status quo in testing
- Players
- Test technologies, now and future
CHAPTER TEN: LEPTOSPIROSIS
- Introduction: Key Comment
- Geographic Markets
- International Programs
- Status quo in testing
- Players
- Test technologies, now and future
CHAPTER ELEVEN: MALARIA
- Introduction: Key Comment
- Geographic Markets
- International Programs
- Status quo in testing
- Players
- Test technologies, now and future
CHAPTER TWELVE: ONCHOCERCIASIS (RIVER BLINDNESS)
- Introduction: Key Comment
- Geographic Markets
- International Programs
- Status quo in testing
- Players
- Test technologies, now and future
CHAPTER THIRTEEN: STDs
- Introduction: Key Comment
- Geographic Markets
- International Programs
- Status quo in testing
- Players
- Test technologies, now and future
CHAPTER FOURTEEN: TUBERCULOSIS
- Introduction: Key Comment
- Geographic Markets
- International Programs
- Status quo in testing
- Players
- Test technologies, now and future
体外诊断(IVD)在发展中国家显示高成长率
2011年10月27日
Global Information, Inc.已开始销售Kalorama Information所发行的报告书「Point of Care Diagnostics for Emerging Infectious Disease Threats (Market Analysis and Technical Considerations) (针对新兴感染疾病威胁的医护站诊断(市场分析与技术考察))」
Kalorama Information分析，容易使用、高温和水少的状况亦能迅速出现结果的体外诊断(IVD)用检查，在IVD上有大幅成长、成为下个市场的机会。报告书预测，检查出疟疾和结核等感染症、钩端螺旋体病和屈公病等奇病的检验，今后5年将成长为2亿5,000万美元的市场规模。报告书由Kalorama Information的分析者Shara Rosen和Diagnostic Consulting Network的社长Brendan O’Farrell共同执笔。
全球7大致死疾病中，结核、疟疾、肝炎、尤其是HIV/AIDS依然剧增，到2020年为止HIV/AIDS及结核将占发展中国家因感染症死亡的绝大多数。由于国际社会对此问题的的反应，形成了市场。针对需要最紧急性处理的疾病，POC试验的销售额以13％的成长率增加，比其他POC诊断市场更剧增。
Shara Rosen述说：「转向迄今被忽视的疾病，因应投入的资金亦扩大。」。「过去10－15年间，政治家和援助团体，不仅是针对感染症的折磨和死亡的原因，亦开始注意到其是阻止经济发展的重大要因。」
|
